Adaptimmune Therapeutics PLC (NASDAQ:ADAP) – Equities researchers at SunTrust Banks upped their FY2017 earnings estimates for Adaptimmune Therapeutics PLC in a note issued to investors on Thursday, according to Zacks Investment Research. SunTrust Banks analyst P. Lawson now anticipates that the biotechnology company will post earnings of ($0.76) per share for the year, up from their previous forecast of ($1.12). SunTrust Banks currently has a “Buy” rating and a $10.00 target price on the stock. SunTrust Banks also issued estimates for Adaptimmune Therapeutics PLC’s Q4 2017 earnings at ($0.26) EPS, Q1 2018 earnings at ($0.25) EPS, Q2 2018 earnings at ($0.27) EPS, Q3 2018 earnings at $0.33 EPS, Q4 2018 earnings at ($0.32) EPS, FY2018 earnings at ($0.50) EPS, FY2019 earnings at ($1.12) EPS, FY2020 earnings at ($0.95) EPS and FY2021 earnings at ($0.56) EPS.
TRADEMARK VIOLATION NOTICE: “SunTrust Banks Analysts Increase Earnings Estimates for Adaptimmune Therapeutics PLC (NASDAQ:ADAP)” was published by Week Herald and is the sole property of of Week Herald. If you are viewing this article on another website, it was stolen and republished in violation of U.S. & international copyright and trademark legislation. The legal version of this article can be accessed at https://weekherald.com/2017/11/15/adaptimmune-therapeutics-plc-forecasted-to-earn-fy2017-earnings-of-0-76-per-share-adap.html.
Several other analysts also recently commented on the stock. Zacks Investment Research downgraded shares of Adaptimmune Therapeutics PLC from a “buy” rating to a “hold” rating in a research report on Friday, November 10th. TheStreet upgraded shares of Adaptimmune Therapeutics PLC from a “d” rating to a “c” rating in a research note on Thursday, November 2nd. Leerink Swann reaffirmed an “outperform” rating and set a $15.00 price objective on shares of Adaptimmune Therapeutics PLC in a research note on Friday, September 8th. BidaskClub upgraded shares of Adaptimmune Therapeutics PLC from a “sell” rating to a “hold” rating in a report on Friday, August 25th. Finally, ValuEngine upgraded shares of Adaptimmune Therapeutics PLC from a “strong sell” rating to a “sell” rating in a report on Thursday, July 20th. One analyst has rated the stock with a sell rating, three have issued a hold rating and three have given a buy rating to the stock. The company currently has an average rating of “Hold” and an average price target of $11.58.
Shares of Adaptimmune Therapeutics PLC (ADAP) traded down $0.16 during midday trading on Monday, reaching $7.43. 6,841 shares of the company’s stock traded hands, compared to its average volume of 259,595. Adaptimmune Therapeutics PLC has a 1-year low of $3.76 and a 1-year high of $9.29.
Institutional investors have recently made changes to their positions in the stock. Matrix Capital Management Company LP acquired a new stake in Adaptimmune Therapeutics PLC in the 2nd quarter valued at about $39,027,000. Baillie Gifford & Co. increased its position in Adaptimmune Therapeutics PLC by 4.2% during the third quarter. Baillie Gifford & Co. now owns 1,379,304 shares of the biotechnology company’s stock worth $11,297,000 after buying an additional 55,996 shares during the period. Renaissance Technologies LLC increased its position in Adaptimmune Therapeutics PLC by 75.4% during the first quarter. Renaissance Technologies LLC now owns 780,800 shares of the biotechnology company’s stock worth $4,302,000 after buying an additional 335,700 shares during the period. Wellington Management Group LLP increased its position in Adaptimmune Therapeutics PLC by 17.4% during the first quarter. Wellington Management Group LLP now owns 608,633 shares of the biotechnology company’s stock worth $3,354,000 after buying an additional 90,110 shares during the period. Finally, Point72 Asset Management L.P. acquired a new position in Adaptimmune Therapeutics PLC during the first quarter worth approximately $2,883,000. Institutional investors own 68.17% of the company’s stock.
Adaptimmune Therapeutics PLC Company Profile
Adaptimmune Therapeutics plc is a clinical-stage biopharmaceutical company. The Company is focused on cancer immunotherapy products based on its Specific Peptide Enhanced Affinity Receptor (SPEAR) T-cell platform. The Company has developed a platform that enables it to identify cancer targets, find and genetically engineer TCR, and produce TCR therapeutic candidates for administration to patients.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Adaptimmune Therapeutics PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Adaptimmune Therapeutics PLC and related companies with MarketBeat.com's FREE daily email newsletter.